At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts.
ERLEADA® is an androgen receptor (AR) inhibitor indicated to treat mCSPC and nmCRPC.
Additional Information
Learn About ERLEADA
Start Early With Erleada — PDF
Erleada Prescribing Information — PDF
Erleada Dosing Information — PDF
Resources to Access — PDF
Learn About J&J COVID-19 Response
Explore Janssen Oncology R&D